1] Z. Anna L, and Z. Robert M, Fractal kinetics of COVID-19 pandemic. medRxiv (2020).
[2] R. Qiurong, et al., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive. Care. Med., 46 (2020) 846-848.
3] Organization, W.H., Coronavirus disease 2019 ( COVID-19): situation report 51(2020).
[4] C. Marco, et al., Features, Evaluation and Treatment Coronavirus (COVID-19), in StatPearls [Internet]. (2020) StatPearls Publishing.
[5] L. Xiaowei, et al., Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal., 10 (2020) 102-108.
[6] S. Catrin, et al., World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int. J. Surg., 76 (2020) 71-76.
[7] A Hussin, R. and B. Siddappa N, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun., 109 (2020) 102433.
[8] Y. Yongshi, et al., The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J. Autoimmun., 109 (2020) 102434.
[9] P. Noah C, et al., The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int. J. Epidemiol., 49 (2020) 717-726.
[10] Z. Lei, and L. Yunhui, Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol., 92 (2020) 479-490.
[11] D. R. Carlos, and M. Preeti N, COVID-19—new insights on a rapidly changing epidemic. Jama., 323 (2020) 1341-1343.
[12] Z. Yadi, , et al., Network -based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell. Discov., 6 (2020) 1-18.
[13] W. Junmei, Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) Through Computational Drug Repurposing Study (2020).
[14] J. Zhenming, et al., Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19. Nature., (2020) DOI: 10.1101/2020.02.26.964882.
[15] A. E. Abdo, Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life. Sci., 248 (2020) 117477.
[16] S. Micholas, and S. Jeremy C, Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface., (2020) DOI: 10.26434/chemrxiv.11871402.v4.
[17] F. Ayman, et al., Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning. ChemRxiv., (2020) DOI: 10.26434/chemrxiv.12049647.v1.
[18] G. Yiyue, et al., A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19. BioRxiv., (2020) DOI: 10.1101/2020.03.11.986836.
[19] S. Balamurugan, et al., Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian. Pac. J. Allergy. Immunol., 38 (2020) 10-18.
[20] W. Manli, et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell. Res., 30 (2020) 269-271.
[21] G. Philippe, et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents., 56 (2020)105949.
[22] V. Thirumalaisamy P, and M. Christian G, The COVID-19 epidemic. Trop. Med. Int. Health., 25 (2020) 278-280.
[23] S. Tanu, A Review of Coronavirus Disease-2019 (COVID-19). Indian. J. Pediatr., 87 (2020) 281-286
[24] C. Wei, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open. Forum. Infect. Dis., 7 (2020) ofaa102.
[25] K. Kai, and C. Jon, Race to find COVID-19 treatments accelerates. Sci., 367 (2020) 1412-1413.
[26] T. Janice Hopkins, Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. B. M. J., 368) 2020 .( m1256
[27] D. Liying, H. Shasha, and G. Jianjun, Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug. Discov. Ther., 14 (2020) 58-60.
[28] A. MHB, Need to test Azithromycin as first-line therapy for Covid-19.
[29] L. Caly, et al., The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res., 178 (2020) 104787.